The Indian Patent Office has refused a patent application filed by the Global Alliance for TB Drug Development, known as TB Alliance, for a combination antibacterial composition and short-course treatment regimen for drug-resistant tuberculosis (DR-TB).
The regimen, known as BPal, combines bedaquiline, pretomanid and linezolid. The order, issued on October 27, 2026, under Section 15 of the Patents Act, 1970, followed two pre-grant oppositions filed in July 2020.
The Controller upheld objections relating to lack of novelty, lack of inventive step, non-patentability and insufficient disclosure, concluding that the application did not meet the requirements of Indian patent law.
For TB survivors and public-health advocates, the decision is an important milestone in efforts to protect access to affordable treatment.…